1Ko J, Lee YH, Hwang SY, et al. Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization [ J ]. Oncogene, 2003,22 ( 30 ) :4679-4689.
2Ha SA, Shin SM, Lee YJ, et al. HCCRBP-1 directly interacting with HCCR-1 induces tumorigenesis through p53 stabilization [ J ]. Int J Cancer,2008,122(3):501-508.
3Bourdon JC. p53 and its isoforms in cancer[ J ]. Br J Cancer,2007,97 ( 3 ) :277-282.
4Hubert WG, Lambert PF. The 23-kilodalton E1 phosphoprotein of bovine papillomavirus type 1 is nonessential for stable plasmid replication in murine C127 cells[ J]. J Virol, 1993,67 (5) :2932-2937.
5Oh YT,Chun KH, Park BD, et al. Regulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1 by protein kinase Cdelta-mediated phosphorylation [ J ]. Apoptosis, 2007,12 (7) : 1339-1347.
6Ko J,Shin SM,Oh YM,et al. Transgenic mouse model for breast cancer: induction of breast cancer in novel oncogene HCCR-2 transgenic mice[ J ]. Oncogene ,2004,23 ( 10 ) : 1950-1953.
7Goswami A, Ranganathan P, Rangnekar VM. The phosphoinositide 3-kinase/Akt1/Par-4 axis:a cancer-selective therapeutic target[ J ]. Cancer Res,2006,66 (6) :2889-2892.
8Barthel A, Ostrakhovitch EA, Walter PL, et al. Stimulation of phosphoinositide 3-kinase/Akt signaling by copper and zinc ions: mechanisms and consequences[ J]. Arch Biochem Biophys, 2007,463 (2) : 175-182.
9Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer [ J ]. Oncogene,2007,26 (9) : 1338-1345.
10Choi Y, Zhang J, Murga C, et al. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells[ J]. Oncogene,2002,21 (34) :5289-5300.
3Chung YJ,Kim JW.Novel oncogene HCCR:its diagnostic and therapeutic implications for cancer.Histol Histopathol,2005,20:999-1003.
4Shin SM,Chung YJ,Oh ST,et al.HCCR-1 interacting molecule "deleted in polyposis 1"plays a tumor-suppressor role in colon carcinogenesis.Gastroenterology,2006,130:2074-2086.
5Jung SS,Park HS,Lee IJ,et al.The HCCR oncoprotein as a biomarker for human breast cancer.Clin Cancer Res,2005,11:7700-7708.
6Ko J,Shin SM,Oh YM,et al.Transgenic mouse model for breast cancer:induction of breast cancer in novel oncogene HCCR-2 transgenic mice.Oncogene,2004,23:1950-1953.
3Ko J, Lee YH, Hwang SY, et al. Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization [ J]. Oncogene, 2003, 22(30) : 4679-4689.
4Chung YJ, Kim JW. Novel oncogene HCCR: its diagnostic and therapeutic implications for cancer [ J ]. Histol Histopathol, 2005, 20 (3) : 999-1003.
5Stahel RA, Zangemeister-Wittke U. Antisense oligonucleotides for cancer therapy -an overview [ J ]. Lung Cancer, 2003, 41 Suppl 1 : S81-88.
6Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer-the time of truth [ J]. Lancet Oncol, 2002, 3 ( 11 ) : 672-683.
7Cho GW, Shin SM, Kim HK, et al. HCCR-1, a novel oncogene, encodes a mitochondrial outer membrane protein and suppresses the UVC- induced apoptosis [J]. BMC Cell Biol, 2007, 8: 50.
8Ha SA, Shin SM, Lee YJ, et al. HCCRBP-1 directly interacting with HCCR-1 induces tumorigenesis through P53 stabilization [ J ]. Int J Cancer, 2008, 122(3) : 501-508.
9Yoon SK, Lim NK, Ha SA, et al. The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma [ J]. Cancer Res, 2004, 64( 15): 5434-5341.
10Jung SS, Park HS, Lee IJ, et al. The HCCR oncoprotein as a biomarker for human breast cancer[J]. Clin Cancer Res, 2005, II (21): 7700-7708.
